Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:02 2025-07-11 EDT			5-day change	1st Jan Change
156.90 ^USD	-0.50%		+0.57%	+8.49%

09:00am	Earnings, inflation data confront resilient US stocks rally	RE
07-11	S&P 500 ends down as tariffs sour sentiment	RE

Trump's tariffs and threatened trade actions

Published on 2025-05-28 at 21:41

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Johnson & Johnson

Earnings, inflation data confront resilient US stocks rally	09:00am	RE
S&P 500 ends down as tariffs sour sentiment	07-11	RE
FDA May Fast Track Drug Reviews for Lower US Prices	07-11	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	07-11	MT
HSBC Adjusts Johnson & Johnson's Price Target to $180 From $184, Keeps Buy Rating	07-11	MT
Wall St Week Ahead-Earnings, inflation data confront resilient US stocks rally	07-11	RE
Morgan Stanley Adjusts PT on Johnson & Johnson to $171 From $169, Maintains Equalweight Rating	07-10	MT
Jabil Inc. : Investing to stay ahead	07-10
Major deals involving U.S. drugmakers and biotechs over the past decade	07-09	RE
Transgene SA Announces Board Changes	07-09	CI
Johnson & Johnson's Q2 Earnings Call Likely to Focus on Guidance, Tariff Impact, BofA Says	07-09	MT
Company earnings: key dates for next week	07-09
Trump says pharmaceutical tariffs could reach 200%	07-08	RE
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	07-08	MT
Sector Update: Health Care Stocks Steady Premarket Tuesday	07-08	MT
Volatility as a Strategy	07-08
J&J: seeks FDA approval for Caplyta for schizophrenia	07-08	CF
Johnson & Johnson Announces the Submission of A Supplemental New Drug Application to the U.S. Food and Drug Administration Based Upon Long-Term Data Evaluating the Safety and Efficacy of Caplyta (Lumateperone) for the Prevention of Relapse in Schizophrenia	07-08	CI
Johnson & Johnson Submits Supplemental NDA for Schizophrenia Treatment Caplyta	07-08	MT
Nanobiotix: NBTXR3 device reclassified as a drug	07-08	CF
Nanobiotix Reports Regulatory Harmonization, New Composition of Matter Patent Filed for JNJ-1900	07-07	MT
Johnson & Johnson Unit Submits EMA Application to Extend Indication of Akeega for Prostate Cancer	07-03	MT
J&J Unit Seeks Indication Extension for Cancer Drug Combo in EU	07-03	MT
US FDA approves Regeneron's blood cancer therapy	07-02	RE

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2024, Johnson & Johnson has 64 manufacturing facilities located in the United States (23), North America (7), Europe (21), Africa and Asia/Pacific (13). The United States accounts for 56.6% of net sales.

Employees

138,100

Sector

Pharmaceuticals

Calendar

07-16 - Q2 2025 Earnings Release

More about the company